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SUMMARY
During breast cancer development, increased presence of leukocytes in neoplastic stroma parallels disease
progression; however, the functional significance of leukocytes in regulating protumor versus antitumor
immunity in the breast remains poorly understood. Utilizing theMMTV-PyMTmodel ofmammary carcinogen-
esis, we demonstrate that IL-4-expressing CD4+ T lymphocytes indirectly promote invasion and subsequent
metastasis of mammary adenocarcinomas by directly regulating the phenotype and effector function of
tumor-associated CD11b+Gr1-F4/80+ macrophages that in turn enhance metastasis through activation of
epidermal growth factor receptor signaling in malignant mammary epithelial cells. Together, these data indi-
cate that antitumor acquired immune programs can be usurped in protumor microenvironments and instead
promote malignancy by engaging cellular components of the innate immune system functionally involved in
regulating epithelial cell behavior.INTRODUCTION
Clinical and experimental studies have established that chronic
infiltration of neoplastic tissue by leukocytes, i.e., chronic inflam-
mation, promotes development and/or progression of various
epithelial tumors (de Visser et al., 2006; Mantovani et al., 2008);
however, the organ-specific cellular and molecular programs
that favor protumor, as opposed to antitumor, immunity are
incompletely understood. Although some subsets of leukocytes
certainly exhibit antitumor activity, including cytotoxic T lympho-
cytes (CTLs) and natural killer (NK) cells (Dunn et al., 2006), other
leukocytes,most notablymast cells, B cells, dendritic cells, gran-
ulocytes, and macrophages, exhibit more bipolar roles, by virtue
of their capacity to either hinder or potentiate tumor progression
(de Visser et al., 2005; Mantovani et al., 2008).Breast cancer development is characterized by significant
increases in the presence of both innate and adaptive immune
cells, with B cells, T cells, and macrophages representing the
most abundant leukocytes present in neoplastic stroma (DeNardo
and Coussens, 2007). Retrospective clinical studies in human
breast cancer have revealed that high immunoglobulin (Ig) levels
in tumor stoma (andserum), and increasedpresenceofextra follic-
ular B cells, T regulatory (Treg) cells, and high ratios of CD4/CD8 or
TH2/TH1 T lymphocytes in primary tumors or in draining lymph
nodes (LNs) correlate with tumor grade, stage, and overall patient
survival (Bates et al., 2006; Coronella-Wood and Hersh, 2003;
Kohrt et al., 2005); thus, some facets of adaptive immunity might
indeed be involved in fostering cancer development in the breast.
However, experimental studies have demonstrated that
macrophages in primary mammary adenocarcinomas regulateSIGNIFICANCE
DeNardo and colleagues demonstrate a tumor-promoting role for TH2-CD4
+ T lymphocytes that elicit protumor, as opposed
to cytotoxic bioactivities of tumor-associated macrophages and enhancement of prometastatic epidermal growth factor
receptor signaling programs in malignant mammary epithelial cells. This work reveals a protumor regulatory program
involving components of the acquired and cellular immune systems that effectively collaborate to promote pulmonary
metastasis of mammary adenocarcinomas, and identifies cellular targets, namely CD4+ T effector cells and IL-4 for anti-
cancer therapy.Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc. 91
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erties (Lin and Pollard, 2007), as well as foster pulmonary metas-
tasis by providing epidermal growth factor (EGF) to malignant
mammary epithelial cells (MECs) and thereby enhancing their
invasive (and metastatic) behavior (Pollard, 2004). Based on
these seemingly disparate observations, we sought to determine
whether adaptive immunity also fosters malignancy in the breast
by regulating the phenotype or effector functions of tumor-asso-
ciated macrophages (TAMs) and either activating their protumor
properties or alternatively by suppressing their antitumor capa-
bilities. To address this, we utilized an aggressive transgenic
mouse model of murine mammary adenocarcinoma develop-
ment (MMTV-PyMT mice) (Guy et al., 1992) where late-stage
carcinogenesis and pulmonary metastasis are regulated by
colony stimulating factor (CSF)-1 and tissue macrophages (Lin
et al., 2001). We evaluated MMTV-PyMT mice harboring homo-
zygous null mutations in genes regulating development of
specific lymphocyte subtypes and found that CD4+ T cells
potentiate pulmonary metastasis of mammary adenocarci-
nomas indirectly by enhancing aspects of protumor immunity
mediated by TAMs.
B
C
A Figure 1. Concomitant Recruitment of Adaptive
and Innate Immune Cells in Breast Cancers
(A) The number of CD68+, CD20+, CD4+, and CD8+ cells
was analyzed in patient samples of normal/hyperplastic
breast tissue (n/h; n = 9), ductal carcinoma in situ (DCIS;
n = 6), and invasive ductal carcinomas (IC; n = 150) using
tissue microarrays. Representative 103 and 403 images
are shown and the average number of positive cells as
depicted reflects themean number of cells in each disease
stage, evaluated by counting all high power fields (203)
per tissue section (1.1 mm)/two sections/patient. *p <
0.05 by Mann-Whitney.
(B, C) CD4+ and F4/80+ cell presence was evaluated
during MMTV-PyMT mammary tumor development and
is depicted by representative images in normal mammary
tissue (-LM) and tumors from 76 and 110-day-old PyMT
mice. CD4+ or F4/80+ cells were quantitatively assessed
and data reflects the mean number of positive cell evalu-
ated in 10 high-power fields (203) per tumor, n = 4 mice
per group.
Graphs are depicted as mean values and standard error of
the mean (SEM) in all panels.
RESULTS
CD4+ T Cells Regulate Pulmonary
Metastasis of Mammary
Adenocarcinomas
As observed in several types of solid tumors,
human breast adenocarcinomas are character-
ized by infiltration of both innate and adaptive
immune cells (Figure 1A). Immunohistochemical
(IHC) detection of CD68+ myeloid cells (macro-
phages), CD4+ and CD8+ T cells and CD20+
B cells in human breast cancer reveals an
increase in each cell type paralleling cancer
development (Figure 1A). Given the critical
role of adaptive immunity in regulating innate
immune cell effector function in chronic inflam-
matory diseases, and in some mouse models of cancer devel-
opment (de Visser et al., 2005), we hypothesized that B and/
or T lymphocytes might exert a functional role in regulating
protumor properties of myeloid cells during mammary carcino-
genesis. Because infiltration of CD4+ T cells and F4/80+
macrophages increases progressively during mammary carci-
nogenesis in MMTV-polyoma middle T (PyMT) mice (Figures
1B and 1C), similar to human breast cancer development
(Figure 1A), we addressed this hypothesis by generating PyMT
mice harboring homozygous null mutations in the recombinase
activating gene-1 (RAG1) functionally impairing development of
B and T cells, i.e., PyMT/RAG1/, and compared them for char-
acteristics of neoplastic progression to PyMT mice lacking B
cells, i.e., PyMT/JH/, versus selective subsets of T cells, i.e.,
PyMT/CD4/, PyMT/CD8/ and PyMT/CD4//CD8/ mice.
Strikingly, we found no gross histopathological or quantitative
differences between these cohorts when evaluated for primary
tumor latency, tumor burden, or tumor angiogenesis as a function
of complete or selective lymphocyte deficiency (Figures 2A–2D;
see Figure S1 available online). In contrast, selective loss of
CD4+ T cells in either PyMT/RAG1/, PyMT/CD4//CD8/,92 Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc.
Cancer Cell
Immune Regulation of Mammary Cancer Metastasis25
20
15
10
 5
 0
Tu
m
or
 B
ur
de
n 
(1
00
0x
m
m
3 )
B C D
%
 T
um
or
 F
re
e 
A
ni
m
al
s
PyMT/RAG1+/-
PyMT/RAG1-/-
PyMT/RAG1+/-
PyMT/RAG1-/-
PyMT/JH+/-
PyMT/JH-/-
PyMT/CD4+/-CD8+/-
PyMT/CD4-/-CD8+/-
    d95      d110      d95     d110       d95      d110  
25
20
15
10
 5
 0
25
20
15
10
 5
 00 12040 80
0
100
25
50
75
A
days
E
PyMT/RAG1+/- PyMT/RAG1-/-
PyMT/JH-/- PyMT/CD4-/-CD8-/-
F Metastatic Foci/Lung Section (d110)
1007550250
*
*
*
PyMT/RAG1+/-
PyMT/RAG1-/-
PyMT/JH+/-
PyMT/JH-/-
PyMT/CD4+/-CD8+/-
PyMT/CD4-/-CD8-/-
PyMT/CD4+/-CD8-/-
PyMT/CD4-/-CD8+/-
Metastatic Foci/Lung Section (d110)
100755025
*
*PyMT/CD4-/-CD8-/-
PyMT/CD4-/-CD8-/- + CD4+
PyMT/CD4+/- + IgG
PyMT/CD4+/- + anti-CD4
6
5
4
2
0
1
3
C
D
45
- /K
er
at
in
+  c
el
ls
/
m
l b
lo
od
 (x
10
00
) * *
*
RA
G1
+/
-
RA
G1
-/-
CD
4+
/-
CD
4-
/-
Ig
G
an
ti-
CD
4
G
PyMT
  R
el
at
iv
e 
Py
M
T 
m
R
N
A
H
*
PyMT/RAG1
I
5.0 mm
4
2
0
1
3
+/- -/-
0
Figure 2. CD4+ T Cells Promote Metastasis, but
Not Primary Tumor Development
(A) Mammary adenocarcinoma incidence in PyMT/
RAG1+/ and PyMT/RAG1/ mice (n = 15 and 18
mice/group, respectively) is depicted as percentage
of tumor-free mice. Mice were considered to be tumor
free until a palpable mass (>4.0 mm) persisted for
longer then 4 days. No statistical differences between
cohorts were observed as evaluated by Wilcoxon test.
(B–D) Total tumor burden of PyMT/RAG1 (B), PyMT/JH
(C), and PyMT/CD4/CD8 (D) cohorts evaluated at
both 95 and 110 days of age, shown as mm3 (n = > 20
mice per cohort). Tumor size was determined by
caliper measurement and multiple tumors in one
animal were added together. No statistical differences
between groups were found as evaluated by Mann-
Whitney test.
(E) Representative lung tissue sections depicting
metastatic tumor burden from 110-day-old PyMT/
RAG1/, PyMT/JH/, PyMT/CD4//CD8/ mice
following hematoxylin and eosin (H&E) staining
(53 magnification).
(F) Quantification of metastatic foci/lung section/
mouse from 110-day-old PyMT/RAG1, PyMT/JH,
PyMT/CD4/CD8, PyMT/CD4, PyMT/CD8 cohorts.
Each lung was serially sectioned and six sections 100
mm apart were H&E stained and total number of meta-
static foci (greater then 5 cells) quantified. Each of the
six sections was averaged per mouse (n = > 20
mice per cohort).
(G) Circulating carcinoma cells were analyzed by flow
cytometry and counted as the number of cytokeratin+/
CD45 cells in blood from 110-day-old PyMT/RAG1+/
(n = 10),PyMT/RAG1/ (n = 10),PyMT/CD4+/ (n = 20),
PyMT/CD4/ (n = 15), or 110-day old PyMT mice
treatedwithanti-CD4depleting IgG (n= 8) or IgGcontrol
(n = 6) for 18 days. Data are depicted as the mean
number of carcinoma cells per milliliter of blood.
(H) PyMT mRNA expression in circulating blood cells.
RNA from whole blood cells of 110-day-old PyMT/RAG1+/ and /RAG1/ mice was evaluated for PyMT mRNA gene expression by RT-PCR (25 cycles) (n = 8
mice/group). Results from ethidium bromide stained gels are depicted following quantification of pixel density using GelDoc software .
(I) Average number of metastatic foci/lung section/mouse from 110-day-old PyMT/CD4+/ mice treated with anti-CD4 depletion antibody (GK1.5) versus IgG
control (CD4+/ IgG) or PyMT/CD4/CD8/ mice following adoptive transfer of naive CD4+ T cells (CD4+ rescue). Each lung was serially sectioned and
assessed as described above. Twenty mice were used for PyMT/CD4/CD8/, six mice for CD4+ rescue, and eight mice for CD4+/ IgG or GK1.5 groups.
(B–I) SEM is shown and asterisk denotes p < 0.05 by Mann-Whitney.or PyMT/CD4//CD8+/ mice resulted in significant attenua-
tion of pulmonary metastasis including reduced numbers of
metastatic foci, decreased tumor burden in lungs (Figures
2E and2F), decreased presence of circulating CD45-cytokera-
tin+ carcinoma cells (Figure 2G), and cells expressing PyMT
mRNA (Figure 2H) in peripheral blood (PB). To verify that
the attenuated metastatic phenotype of CD4-deficient/PyMT
mice was specifically due to lack of CD4+ T cells, as opposed
to a genetic anomaly in homozygous null mice, we depleted
85-day-old PyMT mice of CD4+ T cells for 25 days and
again found reduced pulmonary metastasis (Figure 2I) and
presence of circulating carcinoma cells in PB (Figure 2G). In
contrast, adoptive transfer of naive CD4+ T lymphocytes
into PyMT/CD4//CD8/ mice significantly enhanced
pulmonary metastasis (Figure 2I), together indicating that
CD4+ T lymphocytes mediate metastasis of late-stage malig-
nant mammary epithelial cells in a CD8+ CTL-independent
manner.CD4+ T Cells Regulate Macrophage and Immature
Myeloid Cell Phenotype and Effector Bioactivity
Because the attenuated metastatic phenotype of PyMT/CD4/
micemirrored tissuemacrophage deficiency previously reported
by Pollard and colleagues (Lin et al., 2001), we addressed the
possibility that CD4 deficiency might result in altered myeloid
cell presence and/or function in late-stage carcinomas. Using
flow cytometry and IHC analysis, we found no change in CD45+
leukocyte infiltration in primary adenocarcinomas of 95 and
110-day-old PyMT mice resulting from CD4+ T cell-deficiency
(Figures 3A and 3B). In addition, using flow cytometry to evaluate
the spectrum of leukocytes infiltratingmammary carcinomas, we
found no significant variation in leukocyte composition including
CD11b+Gr1-F4/80+macrophages or CD11b+Gr1HiF4/80 imma-
ture myeloid cells (IMCs) (Figure 3C).
Once in tissues, however, the differentiation state, phenotype,
and effector functions of myeloid cells, including macrophages
and IMCs, can be directly regulated by their immuneCancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc. 93
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Figure 3. CD4+ T Lymphocytes Do Not
Regulate Leukocyte Infiltration but Instead
Regulate Bioeffector Function of Myeloid
Cell Subsets
(A) Immunodetection of CD45+ cells in 95-day-old
PyMT/RAG1+/ and PyMT/RAG1/ mammary
carcinomas. Representative 203 images are
shown.
(B) Flow cytometric analysis of CD45+ cells in
tumors from 95 and 110-day-old PyMT/RAG1
and PyMT/CD4 mice. Data are depicted as the
mean percent of live cells ± SEM, n = 4 mice per
cohort.
(C) Flow cytometric analysis of individual leuko-
cyte populations as a percent of total CD45+ cells
in mammary carcinomas of PyMT mice during
progression and in day 95 tumors from RAG1-
and CD4-deficient/PyMT mice. Data are depicted
as the mean value from four mice/cohort ± SEM.
No statistical differences were found between
groups by Mann-Whitney test.
(D–L) Cytokine expression by TAM. Tumor-associ-
ated CD45+F4/80+Gr1 macrophages were iso-
lated by dual magnetic and flow sorting of
mammary tumors from 95 day-old PyMT/CD4+/
and PyMT/CD4/ mice (n = 3/cohort). Cytokine
expression (TNF-a, IL-6, IL-12p40, IL-1b, IL-10)
was assessed by ELISA of conditioned medium
or by quantitative reverse transcriptase-poly-
merase chain reaction (qRT-PCR; Nos2, Arg1,
Tgfb and Vegf-a) from TAMs (50,000) following
18 hr of culture with or without exogenous
recombinant IL-4 (10 ng/ml). Representative
assays of mammary carcinomas from three or
four mice evaluated independently in triplicate
and depicted as mean ± SEM.
(M–Q) Analysis of tumor-derived IMC phenotype
in PyMT/CD4/ mice. Tumor-associated CD45+
CD11b+Gr1Hi IMCs were isolated by flow from
mammary tumors of 95-day-old PyMT+/CD4+/
and PyMT/CD4/ mice (n = 3/cohort). Isolated
cells were lysed and RNAs assessed by qRT-
PCR as described above. Representative assays
from two independent cohorts each run at least
in triplicate are depicted as mean values ± SEM.
Asterisk denotes p < 0.05 by Mann-Whitney in all
panels.microenvironment. The bioactive state of macrophages, for
example, correlates with classical TH1 and TH2 nomenclature
and is often referred to as M1 (classical) or M2 (alternative) acti-
vation, respectively (Mantovani et al., 2007). Classically acti-
vated M1 macrophages are regulated by TH1 cytokines like
IFNg, TNF-a, and granulocyte-monocyte-colony stimulating
factor (GM-CSF) that, in part, enhance macrophage cytotoxic
activity. In contrast, tissue macrophages exposed to TH2 cyto-
kines common to tumors, including interleukin (IL)-4, IL-13 or
IL-10 manifest an alternative (M2) phenotype that can be poten-
tiated by immune complexes, IL-1, IL-21, transforming growth
factor b (TGF-b), and glucocorticoids. Alternatively activated/
M2 macrophages are commonly found associated with solid
tumors and are thought to possess immunosuppressive, proan-
giogenic and pro-tissue remodeling bioactivities, as well as
expressing high levels of EGF (Leek et al., 2000; Mantovani
et al., 2007).94 Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc.Thus, we evaluated differentiation/maturation and activation
status of TAMs (Figures 3D–3L) and IMCs from carcinomas of
95-day-old CD4-proficient versus CD4-deficient/PyMT mice
(Figures 3M–3Q). Expression analysis of lineage differentiation
markers, including CD45, F4/80, CD11b, and Gr1, in TAMs
revealed no significant alteration based on CD4+ T cell presence
(Figures S2A and S2B). Although similar percentages of CD45+
CD11b+Gr1-F4/80+ TAMs infiltrated adenocarcinomas in both
cohorts (Figure 3C), TAMs of CD4-deficient and RAG1-defi-
cient/PyMT mice expressed significantly elevated levels of type
1 cytokines (e.g., TNF-a, IL-6, IL-12p40, and IL-1b) and Nos2
mRNA, indicative of a prevalent M1 TAM phenotype (Figures
3D–3G, Figure S2C) as compared with TAMs from CD4-profi-
cient/PyMT mice (Figure 3I). Conversely, expression of factors
indicative of alternatively activated (M2) TAMs, including argi-
nase-1 (Arg-1) and Tgfb were significantly reduced in TAMs
isolated from mammary tumors of PyMT/CD4/ mice as
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Figure 4. CD4+ T Lymphocytes are TH2 Cells in
Primary Mammary Carcinomas
(A–H) Analysis of cytokine expression by tumor-associated
CD4+ T cells. CD4+ T cells were isolated by flow sorting from
LNs and tumors of 95-day-old PyMTmice and corresponding
negative littermates (n = 4/cohort). Sorted cells were lysed and
RNAs were assessed by qRT-PCR for GATA3, T-bet, FOXP3,
IFNg, IL-4, IL-13, IL-10, and IL-17a expression. Data are
depicted as the mean fold change from the standardized
sample (-LM LN).
(I) Cytokine analysis in CD4+ T cells ex vivo. Tumor-associated
CD4+ lymphocytes were isolated by flow sorting from
mammary tumors of 95-day-old PyMT/CD4+/ mice (n = 3)
and IL-4, IFNg , and IL-17 expression assessed by ELISA after
18 hr of culture prior to (veh, white bars) or following TCR acti-
vation (black bars). Data are represented as the mean of three
replicates.
(J, K) CD4+ T cells repress TAMM1 phenotype. Tumor-associ-
ated CD45+CD3+CD4+ T lymphocytes and CD45+F4/80+Gr1
TAMs were isolated by flow sorting from mammary tumors of
95-day-oldPyMT/CD4+/mice. TAMswere untreated (V,white
bars), or cultured with IFNg (5 ng/ml) and LPS (50 ng/ml) in the
presence of control CD4+ T cells (treated with control IgGs,
gray bars), or activated CD4+ T cells (black bar, Act-CD4).
TNF-a and IL-12p40 expression in conditioned medium evalu-
ated by ELISA after 18 hr of coculture. Representative data
from two independent experiments are depicted.
(A–K) SEM is shown and asterisk denotes p < 0.05 by Mann-
Whitney test.compared with CD4-proficient littermates (Figures 3J and 3K).
Expression levels of IL-10 and Vegf-a were similar in TAMs
from both cohorts (Figures 3H and 3L, Figure S2C). Moreover,
cytokine expression of TAMs isolated from PyMT mice where
CD4+ T cells had been depleted via neutralizing antibodies evi-
denced similar profiles as observed in TAMs of PyMT/CD4/
mice (Figures S2D and S2E).
Yang and colleagues recently reported that CD11b+Gr1Hi
IMCs are recruited into mammary carcinomas and regulate
pulmonary metastasis in PyMT mice via activation of TGF-b-
regulated signaling pathways (Yang et al., 2008). In order to
determine whether CD4+ T cells were also regulating the bioac-
tivity of IMCs, we analyzed their cytokine profile in mammary
carcinomas of CD4-proficient versus deficient PyMT mice
(Figures 3M–3Q, Figure S2F) and found significantly elevated
expression of factors indicative of an M1 activation state (e.g.,
TNF-a and Nos2) with parallel reduction in M2-type factors
(e.g., Arg-1 and Tgfb). Thus, CD4+ T lymphocytes significantly
regulate cytokine and mediator expression in both IMCs and
TAMs in mammary adenocarcinomas.
TAM Phenotype in Mammary Carcinomas
Is Treg Independent
In vitro, both CD4+ T effector and Treg cells have the capacity to
modulate macrophage cytokine expression (Tiemessen et al.,
2007). In order to determine which of these populations
were regulating TAM bioactivity in vivo, we immune-depleted
CD25+ Tregs by treating cohorts of 80-day-old PyMT mice withanti-CD25 IgG (PC61), versus isotype control Ig, for 20 days
and found no differences in expression of M1-type cytokines
(e.g., TNFa, IL-6, IL-12p40, IL-12p35, Nos2) or M2-induced
genes Arg1, IL-10, or Tgfb (Figures S3A–S3C). Thus, CD4+ T
effector lymphocytes, but not CD25Hi Treg cells, significantly
regulate TAM phenotype and bioeffector function.
CD4+ T Lymphocytes in Mammary Adenocarcinomas
Express TH2 Cytokines
To determine whether CD4+ T cells regulated TAM phenotype by
a TH2 cytokine-mediated pathway, we evaluated mRNA expres-
sion of CD4+ T cells isolated fromLNs andmammary carcinomas
of 95-day-old PyMTmice (Figures S4A and S4B) for transcription
factors and effector molecules indicative of Treg, TH1, TH2, or
TH17-type responses. CD4
+ T lymphocytes isolated from drain-
ing LNs (LNs) andmammary carcinomas of PyMTmice exhibited
elevated expression of GATA3 (TH2) and T-bet (TH1) mRNA, but
not FOXP3 (Treg), when compared with LNs of wild-type litter-
mates (Figures 4A–4C) indicating that both TH1 and TH2 effector
lineages were expanded in LNs and in tumors. In order to assess
the functional consequences of these, we assessed the cytokine
expression profile of CD4+ cells and found significant induction
in TH2 cytokines including IL-4, IL-13, and IL-10 and to a lesser
extent the TH1 cytokine IFNg, and by contrast, IL-17a was not
significantly expressed (Figures 4D–4H). These results were
further confirmed by ex vivo activation of CD4+ T lymphocytes
(isolated from spleen, draining LNs, and tumors of PyMT mice)
with anti-CD3/CD28 Ig. Analysis of expression of IL-4, IFNg,Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc. 95
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Figure 5. M2-Activated TAMs Induce Invasive
Behavior in 3D Mammary Epithelial Organoids
(A) Quantitation of invasive organoids following cocul-
ture of TAMs. Stable wild-type MEC (nMEC) or PyMT-
derived MEC (pMEC) organoids were allowed to form
over 14–20days and thencoculturedwithTAMs (48hr).
Representative immunofluorescent images of nMEC
(a, c) and pMEC (b, d) organoids in the presence or
absence of TAMs evaluated for cytokeratin 7 (green),
F4/80 (red), andDAPI (blue) are shown. Representative
bright field images of invasive pMEC organoids in
coculturewith TAMsaredepictedat 203magnification
and 403 inset. TAMs are denoted by red arrows.
(B) Quantification of organoid disruption following
coculture of TAMwith pMECspheroids in the presence
of IL-4 (20 ng/ml), IL-13 (20 ng/ml), IL-10 (10 ng/ml),
IFNg (5 ng/ml), or LPS (50 ng/ml).
(C) Quantification of pMEC organoid disruption
(formed over 14 days) following coculture (48 hr) with
TAMs and/or tumor-associated CD3+CD4+ T cells.
Cocultures were also exposed to exogenous recombi-
nant mouse IL-4 (10 ng/ml) and/or an anti-mouse IL-4
neutralizing antibody (0.5 mg/ml; clone OP06) added
12 hr prior to leukocytes.and IL-17 by enzyme-linked immunosorbent assay (ELISA), and
IFNg and IL-4 by intracellular flow cytometry, and found that acti-
vated CD4+ T cells expressed higher levels of IL-4 than IFNg or
IL-17 (Figure 4I), and that IL-4-expressing CD4+ T cells repre-
sented a larger fraction of the total CD4+ T cells present in
mammary tumors in vivo (Figure S5A).
To determine whether IL-4 produced by CD4+ T cells was
involved in differentially regulating macrophage effector func-
tions, we assessed M1/M2 cytokine profile of TAMs isolated
from CD4-deficient and CD4-proficient/PyMT mice using an ex
vivo assay. We found that brief exposure of primary TAMs (iso-
lated from PyMT/CD4/ or PyMT/RAG1/ adenocarcinomas)
to exogenous IL-4 resulted in significantly reduced M1-type
cytokine expression, simultaneous with enhanced expression
of M2-type factors and mirroring cytokine expression of TAMs
from CD4-proficient/PyMT mice (Figures 3D–3L, Figures S2C–
S2F), thus indicating a dual role for IL-4 and perhaps CD4+
T cells in regulating macrophage polarity.
We next determined if tumor-associated CD4+ T lymphocytes
by virtue of their expression of IL-4 directly repressed TAM M1
phenotype ex vivo. Whereas IFNg/LPS treatment of TAMs led to
increasedTNFaand IL-12expression (indicativeofM1activation),
this effectwas repressed in the presence of activatedCD4+CD25-
T effector cells (Figures 4J and 4K), thus indicating that tumor-
associatedCD4+T lymphocytesactively repressM1TAMeffector
function, while simultaneously fostering a protumor alternative/
M2 TAM phenotype via expression of cytokines like IL-4.
CD4+ T Cells Regulate Macrophage-Induced
MEC Invasive Behavior
To reveal whether CD4+ T cell activation of TAMs translated into
enhanced invasive behavior of MECs, a requirement for metas-96 Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc.tasis in vivo, we utilized an ex vivo three-dimensional (3D) orga-
notypic coculture model with primary murine cells. Primary
MECs were isolated from either 76-day-old PyMTmice (pMECs)
or 12-week-old virgin negative littermates (nMECs), placed in
3D overlay culture and allowed to form stable noninvasive orga-
noids (Figure 5A) as previously described (Debnath et al., 2003).
Following formation of stable organoids (2–3 weeks), CD45+
CD11b+Gr1-F4/80+ TAMs isolated from mammary carcinomas
of 95-day-old PyMT mice (Figures S2A and S2B) were added,
resulting in elaboration of an invasive MEC phenotype in a signif-
icant percentage of organoids (Figure 5A). When invasive pMEC
organoids formed, TAMswere typically localized at the ‘‘invasive
fronts’’ of invading structures (Figure 5A, panels c–f). In addition,
when TAMs were cocultured with pMEC organoids in the pres-
ence of TH2-type cytokines (IL-4 or IL-13), organoid disruption
and formation of invasive structures was significantly enhanced
(Figure 5B) in a TAM and IL-4 dose-dependent manner (Figures
S6A and S6B). In contrast, when IL-4 or IL-13 cytokines
were added to organoids alone (without TAMs), no significant
change in organoid stability or invasive behavior was observed
(Figure 5B) indicating that cytokine stimulation of pMEC invasion
was mediated by TAMs. Analogous results were found utilizing
IL-4-activated TAMs to induce pMEC invasion in standard Boy-
den Chamber migration assays (Figure S6C). In contrast, when
TAMs were cocultured with pMEC organoids in the presence
of M1-type cytokines (IFNg or LPS) or the immunosuppressive
cytokine IL-10, the invasive pMEC phenotype was significantly
inhibited and instead additional stability of organoids was
observed (Figure 5B). Moreover, to evaluate if tumor-associated
CD4+ T cells were involved or perhaps directly regulating TAM-
induced MEC invasion, TAMs and pMEC organoids were ‘‘tricul-
tured’’ with CD4+ T cells isolated from mammary carcinomas of
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(A) Kaplan Meyer analysis of tumor incidence in
PyMT/IL-4Ra+/ and PyMT/IL-4Ra / mice (n =
15/group) depicted as percentage of tumor-free
animals. No statistical differences between
cohorts by generalized Wilcoxon test were found.
(B) Total mammary tumor burden of PyMT/IL-
4Ra+/ and / mice, and PyMT mice treated for
20 days with either IL-4 neutralizing Ig (11B11) or
control IgG and evaluated at day 100, shown as
mm3 (n = > 20 mice per cohort). Tumor size was
determined by caliper measurement and multiple
tumors in one animal were added together.
(C) Quantification of average number of metastatic
foci/lung/mouse of 100-day-old PyMT/IL-4Ra and
PyMT mice treated with either IL-4 neutralizing or
control IgG. Each lung was serially sectioned,
and six sections 100 mm apart were stained by
H&E and total number of metastatic foci (greater
then 5 cells) quantified. Each of the six sections
was summed and each bar represents n R 23
mice for all cohorts and R 12 for Ig-treated
groups.
(D and E) Tumor-associated CD45+F4/80+Gr1
macrophages were isolated by flow sorting of
mammary carcinomas from (D) PyMT/IL-4Ra or
(E) PyMT mice treated with either IL-4 neutralizing
IgG (11B11) or control IgG. ELISA was performed
on conditioned medium from TAMs (50,000) after
18 hr of culture. Quantitative RT-PCR analysis
was performed using the comparative threshold cycle method to calculate fold change in gene expression normalized to GAPDH as reference gene. Represen-
tative assays from three independent cohorts each run at least in triplicate are depicted as the mean fold change from the standardized sample.
(B–E) Data are represented as mean ± SEM, and asterisk denotes p < 0.05 by Mann-Whitney test.95-day-old PyMT mice (Figure S4A), resulting in a significant
enhancement of pMEC invasive organoids in an IL-4 dependent
manner (Figure 5C). Taken together with data from the in vivo
analysis of TAMphenotype, these data indicate that tumor-asso-
ciated TAMs are alternatively (M2) activated by IL-4-expressing
CD4+ T cells, that together induce invasive behavior of MECs,
a bioactivity that is not supported by TAMs isolated from CD4+
T-cell-deficient adenocarcinomas, or when TAMs are ‘‘classi-
cally’’ activated by factors like IFNg or LPS, or engaged in immu-
nosuppressive programs regulated by IL-10.
IL-4 Regulates TAM Phenotype and Pulmonary
Metastasis of Mammary Adenocarcinomas
Because the capacity of tumor-associatedCD4+T lymphocytes to
regulate TAM phenotype and pMEC invasion was dependent on
TH2-type cytokines, we hypothesized that neutralization of IL-4
or its receptors in vivo would mirror the phenotype of CD4-defi-
cient/PyMT mice and limit pulmonary metastasis. To address
this, we generated PyMTmice either harboring a homozygous in-
activatingmutation in the IL-4 receptor alpha (IL4Ra) gene (FVB/n,
N6), or treated PyMT mice with a neutralizing antibody to IL-4.
Similar to CD4+ T-cell-deficient/PyMT mice, both cohorts of
PyMT/IL4Ra/ and IL-4-neutralized/PyMT mice exhibited no
significant change in primary tumor latency or burden as com-
pared with controls (Figure 6A and 6B). However, loss of either
IL-4activityorexpressionof IL4Ra resulted insignificantly reduced
numbers of metastatic foci in lungs and overall attenuation of total
pulmonary metastasis (Figure 6C). Moreover, cytokine analysis ofTAMs isolated frombothPyMT/IL4Ra/and IL-4-depleted/PyMT
mice revealed increased expression of M1-type factors (IL-6,
Nos2, IL-12p35) and reduced expression of M2-type genes
(Arg1andTgfb) ascomparedwithTAMs fromcontrolmice (Figures
6D and 6E) and thus phenocopied the characteristics of TAMs
isolated from CD4+ T cell-deficient/PyMTmice (Figure 3).
IL-4 Signaling Induces Macrophage EGF mRNA
Expression and EGFR-Dependent Invasion and
Metastasis
Because elaboration of the invasion MEC phenotype certainly
involved activation of intracellular MEC signal transduction
programs, we next sought to identify the soluble mediators
released by TAMs following their activation by IL-4 or CD4+
T cells. Thus, we assessed expression of several growth factors
associated with epithelial cell invasion and found that TAMs iso-
lated from CD4-proficient/PyMT mice exhibited elevated levels
of EGF and Tgfb mRNA expression, as compared with TAMs
from CD4+ T-cell-deficient/PyMT mice (Figures 3K and 7A, and
data not shown). In addition, TAMs represent the most abundant
cellular source of EGF mRNA in mammary carcinomas
(Figure S6E). To determine whether enhanced EGF mRNA
expression by TAMs was directly due to IL-4 exposure, we eval-
uated EGF mRNA expression of TAMs following brief exposure
to IL-4, CSF-1, IL-4 plus CSF-1, as compared with pMEC condi-
tioned medium alone, and found that EGF mRNA expression
was significantly enhanced by IL-4, but only in the presence of
CSF-1 or pMEC conditioned medium (Figures 7A and S6D).Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc. 97
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Figure 7. IL-4 and CSF-1 Signaling Intersect and
Regulate Macrophage EGF Expression, pMEC
Invasion, and Metastasis
(A) EGFmRNA expression analysis from CSF-1- and IL-4-
activated TAMs. TAMs were isolated from mammary
tumors of 95-day-old PyMT/CD4+/ or PyMT/CD4/
mice, and placed into culture with CSF-1 (10 ng/ml) and/
or IL-4 (20 ng/ml) for 16 hr. Quantitative RT-PCR analysis
of EGF mRNA expression is depicted as fold change
from vehicle (CD4/ no treatment is set to 1.0) assessed
by the comparative threshold cycle method normalized to
reference gene expression.
(B) Quantification of pMEC organoid disruption following
coculture of TAMs (48 hr) +/ IL-4 (10 ng/ml) or EFGR
small molecule inhibitors PD153035 (0.1 mM) or
BIBX1382 (10 nM). Invasive organoids were counted and
data represented as a percentage of the total organoids
(>100 replicate). Representative data from two inde-
pendent experiments performed in quadruplicate are
depicted.
(C) EGFR signaling regulates metastasis in PyMT mice.
The 110 day-old PyMT mice were treated with the EGFR
small molecule inhibitor PD153035 (25 mg/kg) versus
vehicle (DMSO) by i.p. injection 5 hr prior to analysis (six
mice/group). Presence of circulating carcinoma cells (cy-
tokeratin+CD45) was assessed by FACS evaluation of
live cells in PB.
(A–C) Data are represented as mean ± SEM, and the
asterisk denotes p < 0.05 by Mann-Whitney test.
(D) Schematic representation of TH2 CD4
+ T lymphocytes
and their role in breast cancer metastasis. During early
breast cancer development, increased presence of leukocytes in neoplastic stroma indicates establishment of a proinflammatory microenvironment. When
immune cell infiltrates include high numbers of TH2 CD4
+ T lymphocytes that produce IL-4 and IL-13, M2-type TAMs and IMCs are activated and in turn produce
EGF, thus resulting in activation of a paracrine-mediated enhancement of malignant cell invasion and dissemination into PB and pulmonary metastasis.To establish whether activation of EGF receptor (EGFR)-medi-
ated signaling was necessary for TAM-induced pMEC invasion,
we evaluated effects of EGFR blockade using the 3D coculture
assay, and found that IL-4-regulated TAM-dependent pMEC
invasion was significantly diminished in the presence of EGFR
tyrosine kinase inhibitors (Figure 7B). To determine whether this
translated to a diminishment in metastasis in vivo, late-stage
(day 110) PyMT mice were treated with PD153035 (25 mg/kg)
for 5 hr and the presence of circulating malignant cells quantita-
tively determined. This brief treatment resulted in a significant
decrease in the number of circulating carcinoma cells present in
PB (Figure 7C), similar to observations by Wyckoff et al. (2007).
Taken together, these data indicate that in response to CD4+
T cell-derived IL-4, M2 effector bioactivity is enhanced in TAMs
(and IMCs) that in turn activate invasive and metastatic potential
ofMECs inmammary adenocarcinomas through their production
of proinvasive/metastatic factors such as EGF (Figure 7D).
DISCUSSION
We revealed a provocative and functional role for CD4+ T effector
cells as potentiators of PB dissemination and pulmonary
metastasis of mammary adenocarcinomas through their ability
to regulate protumor properties of TAMs. Specifically, TH2-polar-
ized CD4+ T lymphocytes regulate M1 and M2-type TAM bioac-
tivity by their expression of IL-4. M2-TAMs in turn promote inva-
sive behavior ofmalignantMECs by high-level production of EGF
that subsequently activates MEC EGFR signaling programs, an98 Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc.activity essential for entry into PB, dissemination and outgrowth
in the lung. These findings indicate that when CD4+ T lympho-
cytes are present in a TH2-type tumor microenvironment, they
can promote metastasis by regulating the protumor properties
of TAMs, as opposed to limiting or eradicating malignant cells
by engaging cytotoxic mechanisms. This realization provides
rational for development of anticancer therapeutics that
neutralize the protumor properties of both adaptive and innate
immune cells in the tumor microenvironment, that when deliv-
ered in combination with cytotoxic drugs that bolster antitumor
immunity, might thereby extend survival of breast cancer
patients with advanced disease.
Effector Function of CD4+ T Cells in Solid
Tumors Is Context Dependent
Although our studies have revealed that CD4+ T cells potentiate
dissemination and metastasis of mammary adenocarcinomas,
it is clear that CD4+ T lymphocytes in other contexts exhibit
other bioactivities. Schreiber and colleagues demonstrated
that CD4+ T cell deficiency in methylcholanthrene-initiated
sarcomas enhanced tumor development (Koebel et al., 2007).
By contrast, following two-stage skin carcinogenesis (dimethyl-
benzanthracene plus tetradecanoylphorbol-acetate), CD4+
T cell deficiency was associated with diminished tumor develop-
ment (Girardi et al., 2004). Thus, tumor etiology, in combination
with the tumor microenvironment, regulates CD4+ T cell pheno-
type, and in part determines whether a protumor, as opposed
to an antitumor immune program, is favored. In agreement
Cancer Cell
Immune Regulation of Mammary Cancer Metastasiswith the tissue context-dependent nature of CD4+ T cells, in
a mouse model of skin and cervical carcinoma development
where oncogenes from human papilloma virus type 16 are
expressed behind the keratin 14 promoter/enhancer, skin
carcinoma formation is modestly attenuated by CD4+ T cell defi-
ciency, whereas cervical carcinoma development is significantly
enhanced (Daniel et al., 2005; Daniel et al., 2003), again demon-
strating that immune responses accompanying tumor develop-
ment are organ dependent as opposed to oncogene dependent,
and, based on the neoplastic and immune microenvironment,
can engage either pro- or antitumor immune regulatory
programs.
CD4+ T lymphocytes have been traditionally classified as
either tumor suppressive, such as TH1 effector cells that repress
tumor growth by secretion of IFNg (among other soluble media-
tors) and support of CTL function, or alternatively tumor-
promoting cells, including Tregs, that foster tumor expansion by
suppressing CD8+ CTLs and NK cells (Trzonkowski et al.,
2006). The interplay between TH1 and Tregs in regulating tumor
immunity is likely critical for the etiology of some malignancies,
such as sarcomas (Dunn et al., 2006; Koebel et al., 2007) or
lung adenocarcinomas (Woo et al., 2002). In addition to these,
a new class of CD4+ T cells expressing IL-17 have been identified
(i.e., TH17 cells) that might also regulate chronic inflammation
and promote tumor development when activated in the presence
of TGF-b and IL-6, or IL-23 (Dong, 2008). In our studies, we found
that pulmonary metastasis and M2-bioactivity of TAMs was
potentiated by CD4+ T effector cells that express high levels of
IL-4, IL-13 and IL-10, as compared with expression of IFNg or
IL-17 (Figures 3 and 4), whereas TAM bioactivities were unaf-
fected by immune depletion of CD25+ Treg cells. Moreover,
CD4+ T cells exerted these affects independent of the presence
or absence of CD8+ T cells, indicating that protumor functionality
does not involve suppression of CTL activity.
In addition to indirectly potentiating cancer development by
regulating protumor properties of myeloid cells, research from
several laboratories has revealed that IL-4 and IL-13 regulate
tumor growth through activation of IL-4/13 receptors on epithe-
lial cells. In some human breast carcinoma cell lines, particularly
those that express the estrogen receptor a, IL-4 and IL-13 inhibit
basal and estrogen-induced cell proliferation in vitro and in xeno-
graph models in vivo (Gooch et al., 2002; Nagai and Toi, 2000).
However, in other breast carcinoma cell lines, IL-4 regulates
tumor cell survival by conferring resistance to apoptosis (in vitro)
that translates to chemoresistance in xenographs (Todaro et al.,
2008). Palucka and colleagues reported that CD4+ T cells
directly enhance early tumor development by their production
of IL-13 (Aspord et al., 2007). In contrast to these, we found no
change in the latency or development of primary mammary
adenocarcinomas due to either CD4+ T cell or IL4Ra deficiency,
indicating that in this model system, CD4+ T cells and IL-4 likely
do not provide a survival or proliferative advantage directly to
neoplastic cells. Moreover, using the ex vivo cell-based assay,
we also found no change in MEC proliferation, acinar
morphology, or organoid stability when cocultured with CD4+
T cells alone, or when MECs were given IL-4 or IL-13. Instead,
when cultured together with MECs in the presence of TAMs,
either tumor-derived CD4+ T cells, IL-4, or IL-13 induced signif-
icant changes in organoid morphology consistent with invasivegrowth (Figure 5). Taken together, these data indicate that the
effects of CD4 T cell-derived TH2 cytokines on tumor develop-
ment and progression is likely regulated by the organ microenvi-
ronment or IL-4/13 receptor status on cell in the tumor microen-
vironment.
Clinical evaluation of human breast cancers has revealed that
presence of CD4+ TH2 and Treg cells increase during cancer
development. High percentages of CD4+ T cells positively corre-
late with tumor stage, including metastatic spread to sentinel
LNs and increased primary tumor size (Kohrt et al., 2005).
Perhaps more significant, the ratio of CD4+ to CD8+ T cells or
TH2 to TH1 cells in primary tumors, where CD4
+ or TH2 cells
are more frequent than CD8+ or TH1 cells, correlates with LN
metastasis and reduced overall patient survival (Kohrt et al.,
2005). More recently, unsupervised expression profiling from
breast-cancer-associated stroma revealed a gene signature
predictive of good prognostic outcome (>98%, 5 year survival)
that was functionally enriched for elements of a TH1-type
immune response, including genes suggestive of CTL and NK
cell activity (Finak et al., 2008). Conversely, high levels of
FOXP3+ Treg cells predict diminished relapse-free and overall
survival (Bates et al., 2006). The interpretation based upon these
clinical studies is that the type of CD4+ effector T cell response
elicited in an emergent breast cancer might in part determine
malignant and metastatic potential. Our data provide some
clarity to these profiles wherein we report that TH2-CD4
+
T cells promote metastasis, not by altering CTL responses, but
instead by enhancing the protumor bioactivities of myeloid cells,
and enhancing intracellular signaling cascades (EGF) required
for dissemination and metastasis.
Macrophage-Mediated Pro- versus Antitumor Immunity
Macrophages promote metastasis in several contexts, i.e., by
supporting tumor-associated angiogenesis, inducing local
immunosuppression, or by promoting malignant cell invasion
and entry into circulation (Condeelis and Pollard, 2006);
however, the molecular mechanisms regulating each of these
‘‘hallmark’’ protumor TAM properties have yet to be elucidated.
Macrophages are implicated in tumor angiogenesis (a prerequi-
site for metastasis) by virtue of their capacity to express proan-
giogenic factors including VEGF and matrix metalloproteinase
(MMP)-9 (Giraudo et al., 2004), and by clinical data in human
breast cancers demonstrating their presence correlates with
increased microvessel density (Uzzan et al., 2004). Accordingly,
tissue macrophage deficiency in PyMT mice leads to reduced
angiogenesis, delayed onset of late-stage carcinomas, and
greatly diminished pulmonary metastasis (Lin and Pollard,
2007). By comparison, loss of CD4+ T lymphocytes, similar to
loss of tissue TAMs, results in reduced presence of circulating
carcinoma cells and diminished pulmonary metastasis, but did
not impact microvessel density, character of angiogenic vascu-
lature, or expression of Vegf-a or MMP-9 by TAMs or IMCs.
These distinctions reflect the fact that CD4+ T-cell-derived
factors, including IL-4, regulate only some aspects of TAM
bioactivity, in particular invasive and metastatic properties of
MECs that are EGF dependent; thus, proangiogenic TAMs are
likely regulated by other factors such as hypoxia.
TAMs exhibit immunosuppressive activity via their expression
of arginase, IL-10, and TGF-b (Mantovani et al., 2007). Our dataCancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc. 99
Cancer Cell
Immune Regulation of Mammary Cancer Metastasisdemonstrate that CD4+ T cells and IL-4 induce some but not all
of their immunosuppressive properties, specifically expression
of Arginase-1, TGF-b, and IL-12, but not IL-10, MHCII, or
CD86 (Figure 3 and data not shown). Mantovani and colleagues
reported that some aspects of TAM-mediated immunosuppres-
sion are regulated by intracellular NF-kB signaling (Saccani
et al., 2006). Moreover, Balkwill and colleagues revealed that
ovarian-cancer-associated TAMs, due to IL-1R and MyD88,
maintain an immunosuppressive M2 phenotype dependent on
IKKb (Hagemann et al., 2008). In vivo, IKKb-deficient TAMs
instead exhibit tumor cell cytotoxicity and switch to a classically
activated M1 phenotype (e.g., IL-12high, major histocompati-
bility complex IIhigh, IL-10low, Arginase-1low) that promotes
regression of advanced ovarian carcinomas by induction of
TAM tumoricidal activity and activation of IL-12-dependent
NK cell recruitment (Hagemann et al., 2008). These experi-
mental findings imply that reprogramming TAM phenotype
and/or altering the immune microenvironment to foster anti-
tumor activity could diminish tumorigenicity and improve clinical
outcome.
Mechanisms of TAMs Induced Epithelial Cell
Invasion and Metastasis
Reciprocal interactions between TAMs andMECs together regu-
late mammary carcinogenesis through activation of a paracrine
feed-forward loop involving TAM-expressed EGF and epithe-
lial-expressed CSF-1 (Wyckoff et al., 2004). This paracrine loop
is critical for branching morphogenesis (Gouon-Evans et al.,
2000), as well as for breast carcinoma cells exhibiting ‘‘high-
velocity’’ polarizedmovement (chemotaxis) along collagen fibers
toward blood vessels directed by perivascular macrophages
(Wyckoff et al., 2007). We propose that these heterotypic inter-
actions are further regulated by factors derived from CD4+
T lymphocytes including IL-4, IL-13, and possibly IFNg. Herein,
we demonstrated that activation of TAMs by IL-4, in combination
with factors derived from malignant MECs such as CSF1, regu-
late high-level expression of EGF, that in turn stimulates EGFR-
induced MEC invasive behavior in vitro and MEC entry into PB
and pulmonary metastasis in vivo. As such, a TH2-rich microen-
vironment likely collaborates with existing genetic mutations in
neoplastic cells, and thereby fosters development of highly inva-
sive tumors in vivo.
In addition to EGF, production of TGFb by M2 TAMs, mesen-
chymal support cells, and IMCs also enhances invasive and
metastatic programming of malignant cells (Yang et al., 2008).
Profiling of human breast carcinomas has revealed that
a TGF-b-responsive gene signature predicts lung metastasis
(Padua et al., 2008). Similarly, we found that the absence of
CD4+ T cells also resulted in decreased Tgfb expression in
TAMs (and IMCs) in mammary adenocarcinomas. The prediction
based on these data is that the type of CD4+ effector lymphocyte
response elicited by the neoplastic microenvironment function-
ally modulates critical stromal derived factors, such as EGF
and TGFb, that collaborate with tumor-cell-intrinsic programs
to regulate invasive and metastatic potential.
Summary
Taken together with clinical and experimental studies, our data
indicate that CD4+ T effector lymphocytes potentiate mammary100 Cancer Cell 16, 91–102, August 4, 2009 ª2009 Elsevier Inc.adenocarcinoma metastasis by modulating the protumor
properties of TAMs that in turn enhance the invasive potential
of malignant mammary epithelial cells. Because late-stage
immune-depletion of CD4+ T cells or IL-4 resulted in a significant
diminution in circulating malignant carcinoma cells and reduced
outgrowth of pulmonary metastases, these provocative findings
indicate that anticancer therapeutic strategies targeting the
effector bioactivity of T cells might hold promise for treating
late-stage disease. Although ongoing genetic alterations clearly
play a role in regulating the malignant behavior of a neoplastic
cell, our study in combination with others revealing dominant
roles played by the tumor microenvironment in regulating malig-
nancy, support the long-standing hypothesis (Bissell et al., 1982)
that the host response and microenvironment in which a
neoplastic cell evolves is as critical to its evolution as the genetic
changes occurring within its nucleus.
EXPERIMENTAL PROCEDURES
Animal Husbandry
Micecarrying thePyMTgeneunder thecontrol of theMMTVpromoter in theFVB/
n background were obtained from Dr. Zena Werb (University of California, San
Francisco [UCSF], San Francisco, CA) and have been previously described
(Guy et al., 1992). Generation and characterization of FVB/n mice homozygous
null (/) for RAG-1, CD4 and CD8 have been described previously (de Visser
et al., 2005). Homozygous null JH and IL4Ramice were obtained from Jackson
Laboratories.TogeneratePyMTmiceon theRAG-1/, JH/, CD4/, CD8/,
and IL4Ra/ backgrounds, RAG-1+/, JH+/, CD4+/, CD8+/, and IL4Ra+/
mice were backcrossed into the FVB/n strain to N15, N5, N14, N7, and N6,
respectively, and then intercrossed with PyMTmice to generate breeding colo-
nies of / and +/ PyMT/RAG-1, PyMT/JH, PyMT/CD4, PyMT/CD8, PyMT/
CD4/CD8, and PyMT/IL4Ra mice. Immune depleted mice were injected every
5 days intraperitoneally (i.p.) with either anti-CD4 (400 mg, GK1.5), anti-CD25
(400 mg, PC61), anti-IL-4 (1.0 mg, 11B11), or control rat Ig. All mice were main-
tained within the UCSF Laboratory for Animal Care barrier facility, and all exper-
iments involvinganimalswere approvedby the Institutional AnimalCareandUse
Committee of UCSF.
Primary and Organoid Cell Culture
Primary nMEC and pMEC pools were established by organoid centrifugation
as previously described (Pullan and Strueli, 1996). Briefly, mammary tissue
biopsies were harvested from 76-day-old PyMT female or 12-week-old virgin
negative littermates and digested with Collagenase A 2.0 mg/ml (Roche) and
DNase 2.0 units/ml (Roche) for 2 hr. Organoids were then isolated by differen-
tial centrifugation and grown in culture conditions as previously described
(Pullan and Strueli, 1996). Primary nMECs were used within two passages
and primary pMEC cells were used within ten passages. Three-dimensional
organotypic cultures were established as previously described (Debnath
et al., 2003; Lee et al., 2007). Cultrex basement membrane extract (BME;
R&D Systems) was utilized to limit endotoxin levels. Cocultures with primary
leukocytes were established only after stable organoid structures had formed
(approximately 3 weeks for nMEC, 2 weeks for pMEC). Leukocytes were over-
laid in medium containing 0.5% BME. Formation of invasive acini was as-
sessed every 12 hr for 3 days. The cytokines IL-4 (20 ng/ml), IL-13 (20 ng/
ml), IL-10 (10 ng/ml), IFNg (5.0 ng/ml) (Peprotech), or LPS (1.0 mM/ml) were
added to cocultures 12 hr after leukocytes overlay. Inhibitors PD153035
(0.1 mM, Calbiochem) or BIBX1382 (10 nM, Calbiochem) were added 1.0 hr
prior to the addition of leukocytes. All experiments were repeated two or three
times with separate pMEC pools and individual experiments were run at least
in triplicate.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism and/or InStat Soft-
ware. Specific tests used were Student’s t test, Mann-Whitney (unpaired,
nonparametric, two-tailed), unpaired t test Welch corrected, generalized
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ered statistically significant.
Additional experimental procedures are included in Supplemental Experi-
mental Procedures.
SUPPLEMENTAL DATA
Supplemental Data include six figures and Supplemental Experimental Proce-
dures and can be found with this article online at http//www.cell.com/
cancer-cell/supplemental/S1535-6108(09)00216-5.
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